Ilia Zeltser, MD
Urology · Bryn Mawr, PANPI 1689689473
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,435 of the $89,507 with a category attached, or 75.3%. Johnson & Johnson accounts for 61.7% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2024 at $31,243 and has fallen 68.5% since, to $9,836 in 2025. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $226.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$55K
- Pfizer$9K
- Myovant Sciences Inc.$9K
- Astellas Pharma US Inc$5K
- Dendreon Pharmaceuticals LLC$2K
- AstraZeneca$2K
- plus $6K from 39 others
What the payments were for
- Consulting fees$10,44212%
- Speaking & faculty fees$67,43575%
- Travel & lodging$1,5972%
- Food & beverage$9,67911%
- Education$3540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,507 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 107 | $1,433,000 |
| ErleadaApalutamide | 53 | $751,037 |
| OrgovyxRelugolix | 199 | $598,644 |
| NubeqaDarolutamide | 22 | $296,161 |
| MyrbetriqMirabegron | 46 | $58,132 |
| GemtesaVibegron | 52 | $54,026 |
| Finasteride | 204 | $3,916 |
| Tamsulosin Hcl | 229 | $3,716 |
| Potassium Citrate ErPotassium Citrate | 25 | $3,295 |
| Tadalafil | 53 | $3,215 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 137 | $3,101 |
| Methenamine Hippurate | 30 | $2,365 |
| Trospium Chloride ErTrospium Chloride | 13 | $2,289 |
| Silodosin | 22 | $2,251 |
| Dutasteride | 23 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $5,107 | $1,491,132153 claims |
| Johnson & JohnsonErleada | $55,191 | $751,03753 claims |
| BayerNubeqa | $403 | $296,16122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.
Other urology in Bryn Mawr
- Guy BernsteinBryn Mawr$25K
- Mehrdad SoroushBryn Mawr$20K
- John AndersonBethlehem$2.1M
- Demetrius BagleyPhiladelphia$739K
- Paul SieberLancaster$631K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Anthony DimatteoButler$189K
- Angelo BaccalaAllentown$166K
- Phillip GinsbergPhiladelphia$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.